3种转换酶抑制剂治疗原发性高血压的成本-效果分析  

Cost-effectiveness Analysis of Three Angiotension-converting Enzyme Inhibitors in Treatment of Essential Hypertension

作　　者：李刚[1] 王小丽[2] 周宏[1] 孙世明[1] 

机构地区：[1]四川省人民医院药剂科,成都市610072 [2]四川省妇幼保健院,成都市610071

出　　处：《中国药房》2002年第10期600-601,共2页China Pharmacy

摘　　要：目的 :探讨3种转换酶抑制剂治疗原发性高血压所产生的经济效果。方法 :选择186例原发性高血压患者 ,随机分为3组 ,分别给予依那普利、福辛普利、培哚普利 ,运用药物经济学方法进行分析。结果 :依那普利为治疗原发性高血压成本最小的药物。结论OBJECTIVE:To evaluate the economic effectiveness of three angiotension-converting enzyme inhibitor(ACEI) in treating patients with essential hypertension.METHODS:186 patients with essential hypertension were randomly divided into three groups receiving enalapril,fosinopril and perindopril respectively.The results were evaluated with pharmacoeconomic analysis.RESULTS:In treatment of hypertension,enalapril was minimal in cost.CONCLUSION:Therapeutic effect will be improved and cost decreased when pharmacoeconomic cost-effectiveness analysis is used.

关 键 词：原发性高血压 成本-效果分析 依那普利 福辛普利 培哚普利 药物经济学 

分 类 号：R544.1[医药卫生—心血管疾病] F407.7[医药卫生—内科学]